Gene-edited pancreatic cells have been transplanted into a patient with type 1 diabetes for the first time. They produced ...

Researchers engineered and screened dozens of base editors to precisely target a single mutation without editing other portions of the DNA.

More than a decade ago, scientists harnessed a bacterial molecular machine that identifies and cuts specific sections of DNA, ...

When scientists discovered how bacteria protect themselves against viral invaders, called phages, in the early 2000s, little ...

Last year saw a landmark approval in precision medicine for the first therapy based on clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR associated protein 9 (Cas9) genome ...

CRISPR Therapeutics AG stock has surged nearly 90% since my Buy call in early May, reaching its highest value since February 2024. The rally builds on the historic approval of Casgevy, a gene editing ...

The FDA approved Casgevy, a CRISPR/Cas9 gene-edited therapy, for transfusion-dependent beta-thalassemia (TDT) in patients 12 years and older last week. The market has reacted negatively to the ...

CRISPR Therapeutics had its first FDA-approved product in December 2023, a treatment for sickle cell disease called Casgevy. It’s also developing treatments for cancer and cardiovascular disease using ...

It has been about a month since the last earnings report for CRISPR Therapeutics AG (CRSP). Shares have lost about 5.3% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

CRISPR Therapeutics AG CRSP shares rallied 9.6% in the last trading session to close at $60.08. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) fell 2.9% on Thursday after an insider sold shares in the company. The company traded as low as $42.78 and last traded at $42.22. 282,558 shares ...